{"id":53975,"date":"2023-02-15T23:06:28","date_gmt":"2023-02-15T22:06:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/charles-river-and-purespring-therapeutics-announce-gene-therapy-manufacturing-collaboration\/"},"modified":"2023-02-15T23:06:28","modified_gmt":"2023-02-15T22:06:28","slug":"charles-river-and-purespring-therapeutics-announce-gene-therapy-manufacturing-collaboration","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/charles-river-and-purespring-therapeutics-announce-gene-therapy-manufacturing-collaboration\/","title":{"rendered":"Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration"},"content":{"rendered":"
\n

\nPlasmid CDMO<\/i> alliance supports first gene therapy platform targeting kidney diseases<\/i>\n<\/p>\n

WILMINGTON, Mass.–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics<\/a>, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.\n<\/p>\n

<\/a><\/p>\n

\nSupporting the first gene therapy platform targeting renal diseases, which affect approximately 840 million people, or around 10 percent of the global population, the program leverages Charles River\u2019s established plasmid platform, eXpDNA\u2122<\/a>, and decades of experience at the Company\u2019s plasmid DNA manufacturing center of excellence.\n<\/p>\n

\nPurespring is engaged in the development of novel therapies which have the potential to stop or significantly slow down chronic kidney diseases for which there is no current therapy available, except for dialysis or transplantation. With an innovative focus on the podocyte, a specialized kidney cell type implicated in many kidney diseases, Purespring\u2019s Adeno Associated Virus (AAV) based gene therapy presents a lower-dose, local delivery approach which maximizes both safety and efficacy, as well as lowering the cost of goods.\n<\/p>\n

\nPlasmid DNA CDMO Services
\n
<\/b>Expanding its comprehensive cell and gene therapy portfolio to span plasmid DNA, viral vector, and cell therapy production, through the acquisitions of Cobra Biologics, Vigene Biosciences, and Cognate BioServices in 2021, and in addition to recent expansion projects, Charles River offers end-to-end support and supply chain simplification for developers seeking to accelerate their program while ensuring the highest quality control.\n<\/p>\n

\nThe eXpDNA plasmid manufacturing platform builds on Charles River\u2019s proven plasmid DNA CDMO capabilities and processes, fine-tuned over decades successfully supporting vaccine and advanced therapy clients through clinical trials and beyond.\n<\/p>\n

\nFor more information, watch <\/i>Sustainable Plasmid DNA Strategies<\/i><\/a>, a case study webinar presented by Andrew Frazer, PhD, Associate Director Scientific Solutions, Charles River, and Amanda Weiss, Vice President, Chemistry, Manufacturing and Controls (CMC), Purespring Therapeutics, available on demand.<\/i>\n<\/p>\n

\nApproved Quotes<\/b>\n<\/p>\n